OrbiMed Closes $3 Billion Across Two Healthcare Venture Funds

By Grace Kim

OrbiMed Advisors has closed $3 billion across two healthcare venture funds, the Wall Street Journal reported in an exclusive. The raise ranks among the largest dedicated healthcare venture fundraises of the past three years.

The headline figure — $3 billion split between two parallel vehicles — confirms what limited partners and healthcare specialists have been waiting to see: that big institutional money is back underwriting biotech, medical device and healthtech startups at scale.

What does the WSJ exclusive confirm?

The Wall Street Journal's scoop locks in three concrete data points: $3 billion in total capital, two distinct funds, and OrbiMed Advisors as the manager. The dual-vehicle structure mirrors a pattern common across healthcare-specialist managers, who typically segment capital by stage or instrument across parallel pools.

For the broader venture market, the optics matter as much as the dollars. A nine-figure commitment to a single healthcare-specialist manager signals that limited partners are willing to back long-duration, science-heavy bets after two lean years for biotech primary capital.

The biggest read: when a healthcare-dedicated firm closes $3 billion in one fundraise cycle, the rest of the asset class notices.

Why a two-fund structure?

Venture firms regularly close multiple vehicles in the same fundraising cycle — typically one for early-stage venture, another for growth equity, private credit or royalties. The two-fund template reported here fits that segmentation: one pool for venture-stage equity, another for later-stage or non-dilutive structures.

Healthcare specialists have used the dual-vehicle approach for decades to give limited partners a choice between higher-octane venture exposure and steadier cash-yielding instruments. OrbiMed has historically run several parallel pools, and the WSJ's two-fund framing fits that operating model.

What does the timing tell us?

OrbiMed's $3 billion lands as biotech indices trade well off their 2021 highs but materially above their late-2023 troughs. Public-to-private valuations have begun to converge, and several specialist managers have publicly raised new vehicles through 2024 and into 2025. OrbiMed's raise is the largest single healthcare-dedicated commitment reported in that window.

The capital, once deployed, will flow into therapeutic developers, medical device makers, diagnostics platforms and digital health companies — the four buckets healthcare specialists typically underwrite. Limited partners backing the funds are betting that biotech IPOs and strategic M&A continue to reopen through 2026.

What to watch next?

Granular details will surface in coming filings. Watch for each vehicle's final close size, the vintage year, the listed investment strategy, and the lineup of returning versus new limited partners. Those data points will tell the market whether OrbiMed expanded its LP base or mostly re-upped existing investors — the cleaner read on actual demand.

The bottom line: a $3 billion commitment to a single healthcare venture manager tells you institutional buyers are still in this market, and they're writing bigger checks than they did a year ago.